Participants 36 93 4
chronic hepatitis B patients treated with different doses
Participants 191 319 4
peripheral blood lymphocytes in the chronic hepatitis B patients treated with different doses of recombinant hepatitis B vaccine
Participants 329 420 9
Seventy-two chronic hepatitis B patients who did not use any anti-HBV drugs within 6 months
Participants 516 617 3
The patients in different groups were treated with different doses of recombinant hepatitis B vaccine
Participants 699 747 3
All patients were followed up for 24 weeks (W24)
Participants 1133 1255 5
The proportion of patients who were ELISPOT positive was higher in the groups treated with recombinant hepatitis B vaccine
Participants 1580 1651 3
In the placebo group, none of the patients showed undetectable HBV DNA,
